Literature DB >> 19228622

Gene-expression signatures in breast cancer.

Christos Sotiriou1, Lajos Pusztai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19228622     DOI： 10.1056/NEJMra0801289

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  506 in total

1.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Authors:  Lisa A Carey; Hope S Rugo; P Kelly Marcom; Erica L Mayer; Francisco J Esteva; Cynthia X Ma; Minetta C Liu; Anna Maria Storniolo; Mothaffar F Rimawi; Andres Forero-Torres; Antonio C Wolff; Timothy J Hobday; Anastasia Ivanova; Wing-Keung Chiu; Madlyn Ferraro; Emily Burrows; Philip S Bernard; Katherine A Hoadley; Charles M Perou; Eric P Winer
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

3.  Impact of multigene assays in early stage breast cancer.

Authors:  Shelly S Lo; Kathy S Albain
Journal:  Oncologist       Date:  2011-10-20

4.  Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer.

Authors:  Agnieszka Kolacinska; Wojciech Fendler; Janusz Szemraj; Bozena Szymanska; Ewa Borowska-Garganisz; Magdalena Nowik; Justyna Chalubinska; Robert Kubiak; Zofia Pawlowska; Maria Blasinska-Morawiec; Piotr Potemski; Arkadiusz Jeziorski; Zbigniew Morawiec
Journal:  Mol Biol Rep       Date:  2012-02-09       Impact factor: 2.316

5.  Breast cancer: Should we assess HER2 status by Oncotype DX?

Authors:  Michail Ignatiadis; Christos Sotiriou
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

6.  Empirical Bayes conditional independence graphs for regulatory network recovery.

Authors:  Rami Mahdi; Abishek S Madduri; Guoqing Wang; Yael Strulovici-Barel; Jacqueline Salit; Neil R Hackett; Ronald G Crystal; Jason G Mezey
Journal:  Bioinformatics       Date:  2012-06-08       Impact factor: 6.937

Review 7.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

8.  Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.

Authors:  Pelagia G Tsoutsou; Yazid Belkacemi; Joseph Gligorov; Abraham Kuten; Hamouda Boussen; Nuran Bese; Michael I Koukourakis
Journal:  Oncologist       Date:  2010-11-01

9.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

10.  Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.

Authors:  P Sinn; S Aulmann; R Wirtz; S Schott; F Marmé; Z Varga; A Lebeau; H Kreipe; A Schneeweiss
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.